Literature DB >> 20471478

Mouse models in neurological disorders: applications of non-invasive imaging.

Yannic Waerzeggers1, Parisa Monfared, Thomas Viel, Alexandra Winkeler, Andreas H Jacobs.   

Abstract

Neuroimaging techniques represent powerful tools to assess disease-specific cellular, biochemical and molecular processes non-invasively in vivo. Besides providing precise anatomical localisation and quantification, the most exciting advantage of non-invasive imaging techniques is the opportunity to investigate the spatial and temporal dynamics of disease-specific functional and molecular events longitudinally in intact living organisms, so called molecular imaging (MI). Combining neuroimaging technologies with in vivo models of neurological disorders provides unique opportunities to understand the aetiology and pathophysiology of human neurological disorders. In this way, neuroimaging in mouse models of neurological disorders not only can be used for phenotyping specific diseases and monitoring disease progression but also plays an essential role in the development and evaluation of disease-specific treatment approaches. In this way MI is a key technology in translational research, helping to design improved disease models as well as experimental treatment protocols that may afterwards be implemented into clinical routine. The most widely used imaging modalities in animal models to assess in vivo anatomical, functional and molecular events are positron emission tomography (PET), magnetic resonance imaging (MRI) and optical imaging (OI). Here, we review the application of neuroimaging in mouse models of neurodegeneration (Parkinson's disease, PD, and Alzheimer's disease, AD) and brain cancer (glioma).
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20471478     DOI: 10.1016/j.bbadis.2010.04.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  15 in total

Review 1.  Molecular brain imaging in the multimodality era.

Authors:  Julie C Price
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

Review 2.  Imaging technologies and basic considerations for welfare of laboratory rodents.

Authors:  Jordi L Tremoleda; Jane Sosabowski
Journal:  Lab Anim (NY)       Date:  2015-03       Impact factor: 12.625

Review 3.  Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines.

Authors:  Robert A Floyd; Hugo C Castro Faria Neto; Guy A Zimmerman; Kenneth Hensley; Rheal A Towner
Journal:  Free Radic Biol Med       Date:  2013-02-16       Impact factor: 7.376

4.  Constraint-induced movement therapy as a paradigm of translational research in neurorehabilitation: Reviews and prospects.

Authors:  Wei-Chao Huang; Yun-Ju Chen; Chung-Liang Chien; Haruo Kashima; Keh-Chung Lin
Journal:  Am J Transl Res       Date:  2010-10-03       Impact factor: 4.060

5.  PET imaging of translocator protein (18 kDa) in a mouse model of Alzheimer's disease using N-(2,5-dimethoxybenzyl)-2-18F-fluoro-N-(2-phenoxyphenyl)acetamide.

Authors:  Michelle L James; Nadia P Belichenko; Thuy-Vi V Nguyen; Lauren E Andrews; Zhaoqing Ding; Hongguang Liu; Deepika Bodapati; Natasha Arksey; Bin Shen; Zhen Cheng; Tony Wyss-Coray; Sanjiv S Gambhir; Frank M Longo; Frederick T Chin
Journal:  J Nucl Med       Date:  2015-01-22       Impact factor: 10.057

6.  ELTD1, a potential new biomarker for gliomas.

Authors:  Rheal A Towner; Randy L Jensen; Howard Colman; Brian Vaillant; Nataliya Smith; Rebba Casteel; Debra Saunders; David L Gillespie; Robert Silasi-Mansat; Florea Lupu; Cory B Giles; Jonathan D Wren
Journal:  Neurosurgery       Date:  2013-01       Impact factor: 4.654

7.  Non-invasive imaging of glioma vessel size and densities in correlation with tumour cell proliferation by small animal PET and MRI.

Authors:  Thomas Viel; Philipp Boehm-Sturm; Sara Rapic; Parisa Monfared; Bernd Neumaier; Mathias Hoehn; Andreas H Jacobs
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-11       Impact factor: 9.236

8.  Alterations in pharmacological and behavioural responses in recombinant mouse line with an increased predisposition to catalepsy: role of the 5-HT1A receptor.

Authors:  E A Kulikova; D V Bazovkina; A E Akulov; A S Tsybko; D V Fursenko; A V Kulikov; V S Naumenko; E Ponimaskin; E M Kondaurova
Journal:  Br J Pharmacol       Date:  2016-04-21       Impact factor: 8.739

9.  Promoted Growth of Brain Tumor by the Transplantation of Neural Stem/Progenitor Cells Facilitated by CXCL12.

Authors:  Nai-Wei Yao; Chiao-Chi V Chen; Chen-Tung Yen; Chen Chang
Journal:  Transl Oncol       Date:  2014-05-23       Impact factor: 4.243

10.  Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.

Authors:  Thomas Viel; Sonja Schelhaas; Stefan Wagner; Lydia Wachsmuth; Katrin Schwegmann; Michael Kuhlmann; Cornelius Faber; Klaus Kopka; Michael Schäfers; Andreas H Jacobs
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.